Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us

COVID-19 updates

Picture

COVID-19 Update for 8/6/2020

8/6/2020

 
COVID-19 Vaccines
Sanofi and GlaxoSmithKline received a $2.1 billion grant from Operation Warp Speed to fund clinical trials, scale up manufacturing, and deliver 100 million doses of their COVID-19 vaccine to the U.S. The deal also includes an option for an additional 500 million doses.
 
The Departments of Defense and Health and Human Services, as part of Operation Warp Speed, have awarded Johnson & Johnson $1 billion for the first 100 million doses ($10 per dose) of its experimental COVID-19 vaccine. The supply will be used for clinical trials or provided, at no charge, through a U.S. vaccination program. The U.S. government also has an option for an additional 200 million doses.
 
Moderna has signed some early vaccine supply deals, pricing their COVID-19 vaccine at $32 to $37 per dose or $64 to $74 per two dose regimen. These early deals were for smaller supplies, so larger orders could have a lower cost per dose, but Moderna has not specified what the price might be. A price for a U.S. government purchase has not yet been determined.
 
Novavax announced that in a 131 patient, Phase I trial (NCT04368988), the antibody level increased with all doses of its NVX-CoV2373 COVID-19 vaccine with or without the Matrix-M adjuvant. Either formulation of the vaccine with adjuvant induced neutralizing antibody levels greater than what is seen in recovered COVID-19 patients. The trial was sponsored by the Coalition for Epidemic Preparedness Innovations and performed in Australia. Novavax is evaluating NVX-CoV2373 in a 1,500 patient, Phase II trial in the U.S. and Australia.
 
Zydus is developing a DNA vaccine (ZyCoV-D)
  1. Zydus reported the vaccine was well tolerated in a 7-day review of data in a Phase I trial involving an unspecified number of patients.
  2. Zydus initiated a 1,000 patient trial for ZyCoV-D on 8/6/2020.
COVID-19 Antibodies
Lilly initiated the NIAID sponsored, 2,400 patient, Phase III, BLAZE-2 trial to assess the prophylactic potential of LY-CoV555 in long-term care residents. BLAZE-2 will assess whether a single dose of LY-CoV555 reduces the rate of COVID-19 through 4 weeks and COVID-19 complications through 8 weeks. 
 
The Pharmaceutical Pipeline Tracker COVID-19 Antibody page now includes new clinical trials for two products (BRII-196 and BRII-198) and two new monoclonal products that have also entered clinical testing:
Sinocelltech is evaluating SCTA01 as a potential treatment for COVID-19 infection.
  • Sinocelltech is evaluating SCTA01in a 33 patient, Phase I trial (NCT04483375) that began in June 2020.
Tsinghua University and 3rd People’s Hospital of Shenzhen researchers identified two antibodies for clinical testing. Brii Bioscience is evaluating the two monoclonal antibodies, BRII-196 and BRII-198, that bind to different sites on the SARS-CoV-2 spike protein as potential treatments for COVID-19 infection.
  • Brii is evaluating BRII-196 in a 12 patient, Phase I trial (NCT04479631) that began in July 2020.
  • Brii is evaluating BRII-198 in a 12 patient, Phase I trial (NCT04479644) that began in July 2020.
Tychan is evaluating TY027 as a potential treatment for COVID-19 infection.
  • Tychan is evaluating TY027 in a 25 patient, Phase I trial (NCT04429529) that began in June 2020.
IL-6 inhibitors
BARDA ceased funding IL-6 inhibitor trials evaluating tocilizumab and sarilumab as treatments for severe COVID-19 in August 2020. Tocilizumaband sarilumab have each failed to demonstrate improvements in clinical trials. 
 
In a 28-day, 56-patient, observational study, 28 patients that received sarilumab were compared to 28 that did not receive the drug. Treatment with sarilumab did not improve clinical status or mortality in patients with severe COVID-19 pneumonia and systemic hyperinflammation. The study suggested that sarilumab may speed recovery in patients with minor lung consolidation at baseline. This study used a subset of patients from the Italian, 1,000 patient, COVID-BioB observational study (NCT04318366).

Comments are closed.
    Stay informed, subscribe to the Prescribe Right Pharmaceutical Pipeline Tracker

    Archives

    January 2023
    November 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020

    Categories

    All

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.